Show simple item record

dc.contributor.authorHanna, Catherine R.
dc.contributor.authorO’Cathail, Sean M.
dc.contributor.authorGraham, Janet S.
dc.contributor.authorSaunders, Mark
dc.contributor.authorSamuel, Leslie
dc.contributor.authorHarrison, Mark
dc.contributor.authorDevlin, Lynsey
dc.contributor.authorEdwards, Joanne
dc.contributor.authorGaya, Daniel R.
dc.contributor.authorKelly, Caroline A.
dc.contributor.authorLewsley, Liz Anne
dc.contributor.authorMaka, Noori
dc.contributor.authorMorrison, Paula
dc.contributor.authorDinnett, Louise
dc.contributor.authorDillon, Susan
dc.contributor.authorGourlay, Jacqueline
dc.contributor.authorPlatt, Jonathan J.
dc.contributor.authorThomson, Fiona
dc.contributor.authorAdams, Richard A.
dc.contributor.authorRoxburgh, Campbell S.D.
dc.date.accessioned2022-01-14T20:32:01Z
dc.date.available2022-01-14T20:32:01Z
dc.date.issued2021-12
dc.identifier.citationHanna , C R , O’Cathail , S M , Graham , J S , Saunders , M , Samuel , L , Harrison , M , Devlin , L , Edwards , J , Gaya , D R , Kelly , C A , Lewsley , L A , Maka , N , Morrison , P , Dinnett , L , Dillon , S , Gourlay , J , Platt , J J , Thomson , F , Adams , R A & Roxburgh , C S D 2021 , ' Correction to : Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) (Radiation Oncology, (2021), 16, 1, (163), 10.1186/s13014-021-01888-1) ' , Radiation Oncology , vol. 16 , 230 . https://doi.org/10.1186/s13014-021-01941-zen
dc.identifier.issn1748-717X
dc.identifier.otherPURE: 211735453
dc.identifier.otherPURE UUID: 8f68f15f-a96e-48e8-b463-db33666e2cb8
dc.identifier.otherScopus: 85120734988
dc.identifier.otherPubMed: 34857017
dc.identifier.otherORCID: /0000-0002-8402-8670/work/106597566
dc.identifier.urihttps://hdl.handle.net/2164/17879
dc.descriptionFunding Information: After publication of this article, the authors reported that the Funding information section was incomplete. The following should have been added: “This work was supported by CRUK (Grant Number C61974/A2429).”en
dc.format.extent1
dc.language.isoeng
dc.relation.ispartofRadiation Oncologyen
dc.rightsOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectR Medicine (General)en
dc.subjectOncologyen
dc.subjectRadiology Nuclear Medicine and imagingen
dc.subjectCancer Research UKen
dc.subjectC61974/A2429en
dc.subject.lccR1en
dc.titleCorrection to : Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) (Radiation Oncology, (2021), 16, 1, (163), 10.1186/s13014-021-01888-1)en
dc.typeJournal itemen
dc.contributor.institutionUniversity of Aberdeen.Medicine, Medical Sciences & Nutritionen
dc.contributor.institutionUniversity of Aberdeen.Health Services Research Uniten
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1186/s13014-021-01941-z
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85120734988&partnerID=8YFLogxKen
dc.identifier.vol16en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record